November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
February 2026 in “Stem Cell Research & Therapy” Stem cell therapies show promise for hair regrowth in alopecia areata but need more research for safety and effectiveness.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
Ivarmacitinib effectively regrows hair in severe alopecia areata.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
November 2025 in “Biomedicines” JAK1 inhibitors can help reduce itchiness in atopic dermatitis.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
1 citations
,
December 2024 in “Indian Dermatology Online Journal” Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.
Alopecia Areata causes hair loss and needs treatments that address both physical and emotional health.
11 citations
,
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Hair regrows faster in alopecia areata than skin re-pigments in vitiligo due to differences in stem cells and treatment effects.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
November 2025 in “Journal of Medicinal Chemistry” Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
November 2025 in “Biomedicines” Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.
5 citations
,
June 2024 in “Value in Health Regional Issues” New therapies are needed to reduce the burden of alopecia areata.
3 citations
,
January 2019 in “International Journal of Trichology” The article concludes that treating hair loss requires careful research, understanding the causes, and personalized treatment plans.
Advancements in diagnostics, treatments, and technology have improved hair loss detection and restoration, with some types being reversible.
February 2025 in “Expert Opinion on Drug Metabolism & Toxicology” Future alopecia treatments will improve with targeted therapies and personalized approaches.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
April 2024 in “Journal of clinical medicine” Effective treatment guidelines for frontal fibrosing alopecia are still unclear.